Sectors

TWST
Twist Bioscience Corporation
94.15
1 x 93.98
1 x 94.59
bid
ask
-
1.71
1.78%
09:59 AM
timesize
Ytd196.82%
1y162.77%
94.67
day range
96.15
23.30
52 week range
105.47
Open95.71Prev Close95.86Low94.67High96.15Mkt Cap5.97B
Vol73.47KAvg Vol1.74MEPS-2.13P/E-45.00Forward P/E-118.74
Beta2.11Short Ratio6.32Inst. Own124.18%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0350-d Avg77.60200-d Avg50.231yr Est88.50
Earning
DateForEstimateReportedSurprisesurprise %
2026-08-032026-06-0.5N/AN/AN/A
2026-05-042026-03-0.49-0.71-0.22-44.90%
2026-02-022025-12-0.48-0.5-0.02-4.17%
2025-11-142025-09-0.5-0.450.0510.00%
2025-08-042025-06-0.54-0.470.0712.96%
2025-05-052025-03-0.56-0.66-0.1-17.86%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupDowngradeOutperformIn-Line
2026-06-29GuggenheimUpgradeBuyBuy
2026-06-24BarclaysUpgradeOverweightOverweight
2026-06-15TD CowenUpgradeBuyBuy
2026-06-15Canaccord GenuityUpgradeBuy
2026-06-11Piper SandlerUpgradeOverweightOverweight
Profile
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Holder
DateNameRelationQuantityDescription
2026-02-04CHAN NELSON CDirector33.25KStock Award(Grant)
2026-03-16CHESS ROBERT BRUCEDirector63.61KConversion of Exercise of derivative security
2026-06-23CHO DENNISOfficer105.14KSale
2026-02-04CRANDELL KEITH L.Director103.62KStock Award(Grant)
2026-05-20FINN PATRICK JOHNPresident274.80KSale
2026-06-21GREEN PAULAOfficer120.41KSale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Artisan Partners Limited Partnership6.37M0.0010.23%
2026-03-30ARK Investment Management LLC6.34M0.0010.19%
2025-12-30Vanguard Group Inc5.78M0.009.28%
2026-03-30BlackRock Inc5.55M0.008.92%
2026-03-30EdgePoint Investment5.38M0.008.64%
2026-03-30William Blair Investment Management, LLC5.27M0.008.46%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30ARK Disruptive Innovation Full Composite3.55M0.005.70%
2025-12-30EdgePoint Global Portfolio Series F2.81M0.004.51%
2025-12-30EdgePoint Global2.81M0.004.51%
2026-06-29ARK Innovation ETF2.51M0.004.03%
2026-03-30ARK Genomic Revolution1.96M0.003.14%
2026-06-29Vanguard Total Stock Mkt Idx Inv1.87M0.003.01%